Navigation Links
Loss of gene promotes brain-tumor development, reduces survival, study finds
Date:1/6/2011

COLUMBUS, Ohio New research shows that loss of a gene called NFKBIA promotes the growth of glioblastoma multiforme, the most common and deadly form of brain cancer, and suggests that therapies that stabilize this gene may improve survival for certain glioblastoma patients.

The study was published recently in the New England Journal of Medicine.

"We show that NFKBIA status may be an independent predictor of survival in certain patients with glioblastoma," says senior coauthor Dr. Arnab Chakravarti, chair and professor of Radiation Oncology and co-director of the Brain Tumor Program at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James).

"We also show that this gene plays a key role in glioblastoma behavior, and that it could be useful for predicting treatment outcomes," he says.

An estimated 18, 500 new cases of glioblastoma occur annually among Americans, resulting in 12,760 deaths. Average survival after diagnosis is about 12 to 15 months.

Most cases of the disease are driven by over activity of a gene called EGFR (epidermal growth factor receptor). This study shows that loss of NFKBIA (nuclear factor of kappa-light polypeptide gene enhancer in B-cells inhibitor-alpha) and overexpression EGFR are equally potent at driving glioblastoma development.

It also shows that glioblastoma tumors generally show either abnormally high levels of EGFR or loss of NFKBIA, but not both. Normal levels of both genes also occur.

Chakravarti, along with Markus Bredel, an adjunct associate professor of radiation oncology at Ohio State and their colleagues analyzed data from 790 cases of glioblastoma, which they divided into 10 study sets, for gene deletions, mutations, and expression of NFKBIA and EGFR.

Using glioblastoma cell lines and tumor cells from patients, they examined the influence of the NFKBIA gene on tumor-cell growth and sensitivity to temozolomide, the most effective chemotherapy for glioblastoma. Finally, they compared these findings with the outcomes of 570 glioblastoma patients.

These investigations showed the following:

  • Restoring NFKBIA in tumor cells inhibited their growth and viability and increased the cells' sensitivity to temozolomide.
  • Restoring NFKBIA suppresses the growth of glioblastoma cells that are driven by overexpression of EGFR.
  • Patients with both copies of NFKBIA survive significantly longer than did patients with tumors that have lost a copy of the gene (131 weeks and 57 weeks, respectively).


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Father Channels His Grief into Advocacy, Promotes Simple Actions to Make Hospitals Safer for Children
2. BioMed Realty Trust Promotes Matthew G. McDevitt to Executive Vice President, Real Estate
3. Medical Transcription Services and EHR Provider MxSecure Promotes Tim Erkel to VP, Client Services
4. Hearts and Minds Promotes Wellness; African Americans Living with Mental Illness Have Higher Risk for Other Illnesses.
5. Pinstripe Promotes Jill Schwieters to President of Pinstripe Healthcare
6. Scientific exchange program promotes collaborative quality standards for drugs, food ingredients
7. Scientists find key to gene that promotes cancer metastasis
8. Microfluidics Promotes Scientific University Research Using Nanotechnology with Innovation Incentives
9. Brain Health Expert Says OASIS Promotes Brain Fitness
10. New Anti-Aging Skin Care Line Promotes Penetration
11. Gold Standard/Elsevier promotes medication safety and compliance via New MEDcounselor languages
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Doctor C ... it attended the January ECRM trade show to continue the marketing and distribution of ... C supplement, known for providing 400 percent better absorption than traditional vitamin C supplements. ...
(Date:1/20/2017)... ... 2017 , ... International Protein, a company based out of Australia that focuses ... January ECRM trade show in Hilton Head, SC. , International Protein was founded ... a line of products that would elevate her fitness regime. At this ECRM trade ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is Greater than Sin”: ... woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is ... as an educator interacting with countless women who had little knowledge of the female ...
(Date:1/20/2017)... ... January 20, 2017 , ... D R ... Pressure (OPEP) device, was featured in a study indicating superior performance against competitive ... “Analysis of Three Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Land of More and More”: a ... world hunger, and shares the simple and achievable answer. “The Land of More and ... the Fairview Missionary Church in Angola, Indiana where he works with the children’s ministry ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 18, 2017 The Academy of Managed ... Administration (FDA) for its release today of draft ... decision makers can proactively share clinical and economic ... as emerging therapies awaiting FDA approval. ... that AMCP developed during two multi-stakeholder meetings last ...
(Date:1/18/2017)... 2017  EnteroMedics Inc. (NASDAQ: ETRM ... technology to treat obesity, metabolic diseases and other ... underwritten public offering of units for gross proceeds ... and commissions and offering expenses payable by EnteroMedics. ... A Units, priced at a public offering price ...
(Date:1/18/2017)... India , January 18, 2017 ... Imaging Technologies Market by Type: Global Opportunity Analysis and Industry ... size was valued at $2,544 million in 2015 and is ... CAGR of 8.4% from 2016 to 2022. North ... accounted for over three-fourths market share in 2015. Ionizing breast ...
Breaking Medicine Technology: